Today: 9 June 2026
CCSC stock pops ahead of the bell as Nasdaq deadline looms
9 June 2026
2 mins read

CCSC stock pops ahead of the bell as Nasdaq deadline looms

New York, June 9, 2026, 07:01 ET

CCSC Technology International Holdings Limited jumped in U.S. premarket trade Tuesday. The Nasdaq microcap pointed to more swings with a key listing deadline coming up in less than a week.

CCTG traded at $1.99 as of 7:00 a.m. ET, up $1.51, or 315.28%, from its last close of $0.48, according to Public.com. Premarket volume sat at 37.37 million shares. In premarket hours—before the 9:30 a.m. open—fewer shares can mean sharper price swings.

Nasdaq hadn’t started its regular session. Normal trading runs from 9:30 a.m. to 4:00 p.m. ET. The exchange’s 2026 holiday calendar has the next June closure on Juneteenth, June 19, not Tuesday.

Timing is key here. A Jan. 23 SEC filing shows CCSC has until June 15, 2026, to get back in line with Nasdaq Listing Rule 5550(a)(2), the exchange’s rule for minimum bid price.

Nasdaq rules say listed stocks need to keep a closing bid price of at least $1. That’s the price buyers are quoting near the close. They have to hit that level for at least 10 business days during the compliance period to stay within the rules.

CCSC had tried to tackle the problem before. The company went ahead with a 1-for-10 reverse stock split on Jan. 23, saying in a release published on Nasdaq that it dropped its Class A ordinary shares to roughly 3.41 million from about 34.13 million. A reverse split turns multiple shares into fewer shares and pushes up the stock price per share, but doesn’t affect a holder’s overall stake apart from adjustments for fractions.

CCSC, a holding company set up in the Cayman Islands, runs subsidiaries in Hong Kong, mainland China, and the Netherlands. The company designs, makes, and sells interconnect products such as connectors, cables, and wire harnesses. According to CCSC, its customer base spans over 25 countries.

The broader market firmed up, but that didn’t account for the scale of the jump in CCTG. Nasdaq 100 futures climbed 0.7% at 5:57 a.m. ET on Tuesday, according to Reuters, with chip names pushing higher.

CCSC competes in product markets against much bigger interconnect firms. Amphenol calls itself one of the world’s largest suppliers of interconnect, sensor and antenna products. TE Connectivity sells cable assemblies that link components and equipment. That size difference makes Amphenol and TE bad trading comps for CCTG. But the two offer context for the kind of market CCSC is in.

CCSC posted revenue of $8.47 million for the six months ending Sept. 30, 2025, down 8.2% from last year. The company also recorded a net loss of $0.97 million. CEO Kung Lok Chiu said the latest stretch “demonstrated the resilience of our business” and pointed to “operational efficiency and expense control.” Pressure on the business was evident in the update. PR Newswire

But things could change at the open. A premarket price over $1 doesn’t guarantee CCTG can clear the closing-bid hurdle, and after-hours action in thinly traded microcaps like this can vanish when the bell rings. If CCTG loses the pop before the market closes, the Nasdaq compliance problem is still front and center, not in the rearview.

The main test hits at 9:30 a.m. ET. The next one lands at the close.

Stock Market Today

  • AmpliTech Shares Surge 26.7% on 5G Open RAN Testing Update
    June 9, 2026, 9:16 AM EDT. AmpliTech (AMPG) shares surged 26.7% to $6.57 following its Open RAN testing update at the O-RAN Alliance Global PlugFest Spring 2026. The company's 64T64R Massive MIMO radio, which uses multiple antennas to enhance wireless capacity, was the only one of its kind tested with equipment from major operators including AT&T and Deutsche Telekom. Despite the strong test results, no new sales orders were announced, leaving investors cautious about future revenue impact. AmpliTech reported a 48.6% increase in first-quarter revenue to $5.35 million but remains unprofitable, narrowing its net loss to $1.52 million. The firm holds $18.4 million in cash and securities. Open RAN aims to enable multi-vendor interoperability in 5G networks, a critical push in telecom infrastructure modernization.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Core AI Stock Jumps 474% Premarket, Market Watches Filing
Previous Story

Core AI Stock Jumps 474% Premarket, Market Watches Filing

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus
Next Story

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

Go toTop